Literature DB >> 4862278

Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion.

A Segaloff, M Cuningham, B F Rice, J B Weeth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4862278     DOI： 10.1002/1097-0142(196710)20:10<1673::aid-cncr2820201016>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Authors:  M Salimtschik; H T Mouridsen; J Loeber; E Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.